The approval comes as schools reopen after the holidays amid the Omicron surge.
This approval comes just as most children across the country are returning to school after the winter holiday break — and also as the omicron strain of the coronavirus begins to spike cases in a number of regions and cities.
“Throughout the pandemic, as the virus that causes COVID-19 has continuously evolved, the need for the FDA to quickly adapt has meant using the best available science to make informed decisions with the health and safety of the American public in mind,” said Acting FDA Commissioner Janet Woodcock, M.D.,.
In order to approve the booster for teens, the FDA stated that it, “reviewed real-world data from Israel, including safety data from more than 6,300 individuals 12 through 15 years of age who received a booster dose of the vaccine at least 5 months following completion of the primary two-dose vaccination series.”
The statement added that the approval took into account the current surge of the virus in weighing the risks and benefits of approving the booster.“The data shows there are no new safety concerns following a booster in this population,” they write. “There were no new cases of myocarditis or pericarditis reported to date in these individuals….No new safety concerns have emerged from a population of over 4.
“Children 5 through 11 years of age who have undergone solid organ transplantation, or who have been diagnosed with conditions that are considered to have an equivalent level of immunocompromise, may not respond adequately to the two-dose primary vaccination series,” they write. “Thus, a third primary series dose has now been authorized for this group. This will now allow these children to receive the maximum potential benefit from vaccination.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA authorizes Pfizer COVID-19 boosters for 12- to 15-year oldsThe FDA on Monday authorized Pfizer COVID-19 boosters for 12- to 15-year olds amid the omicron surge as children head back to school.
Consulte Mais informação »
U.S. FDA authorizes Pfizer's COVID-19 booster for 12- to 15-year-oldsThe U.S. Food and Drug Administration on Monday authorized the use of a third dose of the Pfizer and BioNTech COVID-19 vaccine for children ages 12 to 15, and narrowed the interval for booster shot eligibility to five months from six.
Consulte Mais informação »
FDA authorizes Pfizer Covid-19 vaccine boosters for 12- to 15-year-oldsThe US kicked off 2022 amid a massive Covid-19 case spike — driven by the highly contagious Omicron variant — that some experts warn will be different than any other time in the pandemic.
Consulte Mais informação »
FDA expands Pfizer COVID-19 boosters for 12- to 15-year-olds as omicron surgesThe U.S. is expanding COVID-19 boosters as it confronts the omicron surge, with the FDA allowing extra Pfizer shots for children as young as 12.
Consulte Mais informação »
FDA expands Pfizer COVID-19 vaccine booster for ages 12 to 15The FDA expanded Pfizer’s COVID-19 vaccine booster for kids as young as 12. Final approval from the CDC is still needed.
Consulte Mais informação »